文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

蛋白质组学筛选鉴定PF4/Cxcl4为骨髓纤维化的关键驱动因子

Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis.
PubMed 文献 · Leukemia · 2024-07-18

研究对罗米司亭依赖性骨髓纤维化小鼠进行质谱蛋白质组学分析,发现趋化因子PF4/Cxcl4在所有蛋白质组中上调,且在纤维化小鼠血浆和骨髓液中升高。PF4通过表面糖胺聚糖被基质细胞快速内化并促进肌成纤维细胞分化,Cxcl4基因沉默减轻促纤维化表型,糖胺聚糖药理学抑制改善小鼠体内纤维化。

要点

  • PF4/Cxcl4在罗米司亭依赖性骨髓纤维化小鼠的所有蛋白质组中上调,血浆和骨髓液中升高。
  • 高浓度TPO维持培养巨核细胞中PF4的体外合成和分泌,鲁索替尼抑制体内异常PF4表达。
  • PF4通过表面糖胺聚糖被基质细胞快速内化以促进肌成纤维细胞分化,糖胺聚糖抑制改善小鼠纤维化。

核心结论

  • PF4在MPN纤维化进展中起关键作用,中和PF4-糖胺聚糖相互作用是具有潜力的治疗策略。

研究设计与样本

  • 对罗米司亭依赖性骨髓纤维化小鼠进行基于质谱的蛋白质组学研究,分析巨核细胞、血小板和骨髓细胞中的信号通路和蛋白变化。

主要发现

  • PF4/Cxcl4在所有蛋白质组中上调,并在纤维化小鼠的血浆和骨髓液中升高。
  • 高TPO浓度维持培养巨核细胞中PF4的体外合成和分泌,鲁索替尼抑制体内异常PF4表达。
  • PF4通过表面糖胺聚糖被基质细胞快速内化以促进肌成纤维细胞分化。
  • 在TPO饱和共培养条件下,巨核细胞中Cxcl4基因沉默减轻基质细胞的促纤维化表型。
  • 在罗米司亭治疗的JAK2V617F小鼠和MPN患者骨髓活检中检测到广泛的基质PF4摄取和糖胺聚糖沉积改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite increased understanding of the genomic landscape of Myeloproliferative Neoplasms (MPNs), the pathological mechanisms underlying abnormal megakaryocyte (Mk)-stromal crosstalk and fibrotic progression in MPNs remain unclear. We conducted mass spectrometry-based proteomics on mice with Romiplostim-dependent myelofibrosis to reveal alterations in signaling pathways and protein changes in Mks, platelets, and bone marrow (BM) cells. The chemokine Platelet Factor 4 (PF4)/Cxcl4 was up-regulated in all proteomes and increased in plasma and BM fluids of fibrotic mice. High TPO concentrations sustained in vitro PF4 synthesis and secretion in cultured Mks, while Ruxolitinib restrains the abnormal PF4 expression in vivo. We discovered that PF4 is rapidly internalized by stromal cells through surface glycosaminoglycans (GAGs) to promote myofibroblast differentiation. Cxcl4 gene silencing in Mks mitigated the profibrotic phenotype of stromal cells in TPO-saturated co-culture conditions. Consistently, extensive stromal PF4 uptake and altered GAGs deposition were detected in Romiplostim-treated, JAK2V617F mice and BM biopsies of MPN patients. BM PF4 levels and Mk/platelet CXCL4 expression were elevated in patients, exclusively in overt fibrosis. Finally, pharmacological inhibition of GAGs ameliorated in vivo fibrosis in Romiplostim-treated mice. Thus, our findings highlight the critical role of PF4 in the fibrosis progression of MPNs and substantiate the potential therapeutic strategy of neutralizing PF4-GAGs interaction.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Capitanio D, Calledda FR, Abbonante V, et al. Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis. Leukemia. 2024. PMID: 39025985. doi:10.1038/s41375-024-02354-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。